Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications
Abstract
:1. Introduction
2. Overview of lncRNAs
3. Drug Resistance-Related lncRNAs and Malignant Phenotypes in GC
3.1. Drug Resistance-Related lncRNAs and Metastasis
3.2. Drug Resistance-Related lncRNAs and Proliferation
3.3. Drug Resistance-Related lncRNAs and Apoptosis
4. Mechanisms of Drug Resistance-Related lncRNAs in GC
4.1. The lncRNA-miRNA(-mRNA) Network
4.1.1. ceRNA Network
LncRNAs | Expression | Sponging miRNAs | Targets | Functions | Drugs | Refs. |
---|---|---|---|---|---|---|
Upregulating the expression of target genes | ||||||
BLACAT1 | ↑ | miR-361 | ABCB1 | upregulating ABCB1 expression | OXA | [39] |
CRART16 | ↑ | miR-122-5p | FOS | upregulating VEGFD expression | Bevacizumab | [41] |
FENDRR | ↑ | miR-4700-3p | FOXC2 | upregulating FOXC2 expression | VCR, ADM | [131] |
HIF1A-AS2 | ↑ | miR-29c | LOX | upregulating LOX expression | MDR | [134] |
HOTAIR | ↑ | miR-195-5p | ABCG2 | upregulating ABCG2 expression | OXA | [64] |
LINC00922 | ↑ | miR-874-3p | GDPD5 | upregulating GDPD5 expression | DDP | [73] |
MALAT1 | ↑ | miR-22-3p | ZFP91 | upregulating ZFP91 expression | OXA | [78] |
PCAT-1 | ↑ | miR-128 | ZEB1 | upregulating ZEB1 expression | DDP | [130] |
PVT1 | ↑ | miR-3619-5p | TBL1XR1 | upregulating TBL1XR1 expression | DDP | [88] |
Activating signaling pathways | ||||||
ASB16-AS1 | ↑ | miR-3918, miR-4676-3p | TRIM37 | activating NF-kappa B pathway | DDP | [37] |
CRAL | ↓ | miR-505 | CYLD | suppressed AKT activation | DDP | [125] |
D63785 | ↑ | miR-422a | MEF2D | activating VEGF/TGF-β1 pathway | DOX | [46] |
FOXD1-AS1 | ↑ | miR-466 | PIK3CA | activating PI3K/AKT/mTOR pathway | DDP | [52] |
HCP5 | ↑ | miR-3619-5p | PPARGC1A | activating AMPK pathway | 5-FU, OXA | [96] |
HOTAIR | ↑ | miR-126 | VEGFA, PIK3R2 | activating PI3K/AKT/MRP1 pathway | DDP | [61] |
SNHG17 | ↑ | miR-23b-3p | Notch2 | activating Notch2 pathway | DDP | [135] |
TMEM44-AS1 | ↑ | miR-2355-5p | PPP1R13L | inhibiting p53 pathway | 5-FU | [136] |
Regulating the activity of transcription factors | ||||||
EIF3J-DT | ↑ | miR-188-3p | ATG14 | inducing autophagy | 5-FU, OXA | [92] |
FGD5-AS1 | ↑ | miR-153-3p | CITED2 | increasing transactivator activity | 5-FU | [50] |
HCP5 | ↑ | miR-128 | HMGA2 | increasing transcriptional activity | DDP | [56] |
↑ | miR-519d | HMGA1 | increasing transcriptional activity | DDP | [57] | |
HOTTIP | ↑ | miR-218 | HMGA1 | upregulating transcriptional regulator expression | DDP | [65] |
Inducing autophagy | ||||||
LINC01572 | ↑ | miR-497-5p | ATG14 | inducing autophagy | DDP | [71] |
MALAT1 | ↑ | miR-23b-3p | ATG12 | inducing autophagy | DDP, VCR, 5-FU | [76] |
↑ | miR-30b | ATG5 | inducing autophagy | DDP | [77] | |
↑ | miR-30e | ATG5 | inducing autophagy | DDP | [80] | |
Epigenetic modification | ||||||
CRAL | ↓ | miR-505 | CYLD | suppressing AKT activation | DDP | [125] |
HOTAIR | ↑ | miR-17-5p | PTEN | inhibiting the PTEN phosphatase activity | DDP, ADM, MMC, 5-FU | [63] |
Metabolic regulation | ||||||
HAGLR | ↑ | miR-338-3p | LDHA | increasing glycolysis | 5-FU | [54] |
HCP5 | ↑ | miR-3619-5p | PPARGC1A | increasing fatty acid oxidation | 5-FU, OXA | [55] |
SNHG1 | ↑ | miR-216b-5p | HK2 | increasing glycolysis | PTX | [107] |
SNHG7 | ↑ | miR-34a | LDHA | increasing glycolysis | DDP | [137] |
SNHG16 | ↑ | miR-506-3p | PTBP1 | increasing glycolysis | 5-FU | [138] |
Metastasis and angiogenesis | ||||||
CRART16 | ↑ | miR-122-5p | FOS | increasing angiogenesis | Bevacizumab | [41] |
HNF1A-AS1 | ↑ | miR-30b-5p | EIF5A2 | promoting EIF5A2-induced EMT process | 5-FU | [59] |
Apoptosis regulation | ||||||
ADAMTS9-AS2 | ↑ | miR-223-3p | NLRP3 | activating NLRP3 mediated pyroptotic cell death | DDP | [32] |
SNHG6 | ↑ | miR-1297 | Bcl-2 | inhibiting apoptosis | DDP | [93] |
UCA1 | ↑ | miR-513a-3p | CYP1B1 | inhibiting apoptosis | DDP | [100] |
Immune response regulation | ||||||
NUTM2A-AS1 | ↑ | miR-376a | TET1, HIF-1A | inhibiting immune responses | PD-L1 | [85] |
SNHG15 | ↑ | miR-141 | PD-L1 | inhibiting immune responses | PD-L1 | [139] |
Proliferation regulation | ||||||
ANRIL | ↑ | miR-181a-5p | CCNG1 | inhibiting proliferation | DDP | [35] |
SLCO1C1 | ↑ | miR-204-5p, miR-211-5p | SSRP1 | enhancing cell growth, preventing DNA damage | OXA | [91] |
4.1.2. lncRNA-miRNA
4.2. Upstream Regulation of Drug Resistance-Related lncRNAs in GC
4.3. Downstream Regulation of Drug Resistance-Related lncRNAs in GC
4.3.1. Scaffold-like lncRNAs in the Nucleus
4.3.2. Enhancer-like lncRNAs in the Nucleus
4.3.3. Transcription and Translation Functions of lncRNAs in the Cytoplasm
4.4. Epigenetics and Drug Resistance-Related lncRNAs
4.5. Drug Resistance-Related lncRNA-Mediated Regulation of Cell Signaling in GC
5. Metabolism, Tumor Microenvironment, and Drug Resistance-Related lncRNAs
5.1. Metabolism and Drug Resistance-Related lncRNAs
5.2. Tumor Immune Microenvironment and Drug Resistance-Related lncRNAs
5.3. “Cross-Talk” in TME and Drug Resistance-Related lncRNAs
6. Clinical Application of Drug Resistance-Related lncRNAs
7. Conclusions and Perspectives
- Gastric cancer, being one of the most prevalent malignant neoplasms, significantly impacts global population health.
- Drug resistance poses a significant impediment to achieving optimal therapeutic outcomes in the treatment of malignant tumors.
- Long non-coding RNAs (lncRNAs) play a pivotal role in a wide range of pathological and physiological processes, encompassing the regulation of drug resistance.
- What special role do drug-resistant lncRNAs play in the malignant phenotype of gastric cancer?
- Can the ceRNA model be considered as the exclusive regulatory mechanism utilized by lncRNAs in conferring drug resistance to gastric cancer?
- What is the functional significance of lncRNAs among the tumor microenvironment, metabolism, and drug resistance mechanisms in gastric cancer?
- How are drug-resistant lncRNAs used to guide the diagnosis and treatment of gastric cancer?
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ABCB1 | ATP binding cassette subfamily B member 1 |
ACSL4 | acyl-CoA synthetase long chain family member 4 |
AKT | AKT serine/threonine kinase |
AMPK | protein kinase AMP-activated catalytic subunit alpha 1 |
APAF1 | apoptotic peptidase activating factor 1 |
ARHGAP5 | Rho GTPase activating protein 5 |
ATG5 | autophagy related 5 |
ATM | ATM serine/threonine kinase |
ATP | Adenosine triphosphate |
BECN1 | beclin 1 |
CAF | cancer-associated fibroblast |
CBS | cystathionine beta-synthase |
CDKN1A | cyclin dependent kinase inhibitor 1A |
ceRNA | competing endogenous RNAs |
CHIP | STIP1 homology and U-box containing protein 1 |
CNBP | CCHC-type zinc finger nucleic acid binding protein |
CYLD | CYLD lysine 63 deubiquitinase |
DDP | cisplatin |
DNA | Deoxyribonucleic acid |
E2F6 | E2F transcription factor 6 |
EMT | Epithelial to mesenchymal transition |
EZH2 | enhanced by zeste homolog 2 |
FAO | fatty acid oxidation |
FOLFOX | a chemotherapy regimen |
FOXM1 | forkhead box M1 |
GLUT1 | solute carrier family 2 member 1 |
HDAC3 | histone deacetylase 3 |
HK2 | hexokinase 2 |
HMGA2 | high mobility group AT-hook 2 |
hnRNPA1 | heterogeneous nuclear ribonucleoprotein A1 |
HSP70 | heat shock protein family A (Hsp70) member 8 |
HuR | ELAV-like RNA binding protein 1 |
IGF2BP1 | insulin-like growth factor 2 mRNA binding protein 1 |
LDHA | lactate dehydrogenase A |
lncRNA | long non-coding RNA |
LOX | lysyl oxidase |
MDR | multidrug resistance |
METase | methioninase |
MK | midkine |
MREs | miRNA response elements |
mRNA | messenger RNA |
MSCs | mesenchymal stem cells |
ncRNA | non-coding RNA |
NEDD4-1 | NEDD4 E3 ubiquitin protein ligase |
PC | pyruvate carboxylase |
PDCD4 | programmed cell death 4 |
PPARGC1A | PPARG coactivator 1 alpha |
PTBP1 | polypyrimidine tract binding protein 1 |
PTEN | phosphatase and tensin homolog |
RNA | ribonucleic acid |
sncRNA | small non-coding RNA |
SOX2 | SRY-box transcription factor 2 |
SOX9 | SRY-box transcription factor 9 |
SRSF6 | serine and arginine rich splicing factor 6 |
TAM | tumor-associated macrophage |
TET1 | tet methylcytosine dioxygenase 1 |
TIME | tumor immune microenvironment |
TME | tumor microenvironment |
TRIM37 | tripartite motif containing 37 |
TROY | TNF receptor superfamily member 19 |
YWHAZ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
References
- Smyth, E.C.; Nilsson, M.; Grabsch, H.I.; van Grieken, N.C.; Lordick, F. Gastric cancer. Lancet 2020, 396, 635–648. [Google Scholar] [CrossRef]
- Dassen, A.E.; Dikken, J.L.; van de Velde, C.J.; Wouters, M.W.; Bosscha, K.; Lemmens, V.E. Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. Int. J. Cancer 2013, 133, 1859–1866. [Google Scholar] [CrossRef]
- Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Niksic, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Esteve, J.; et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018, 391, 1023–1075. [Google Scholar] [CrossRef]
- Duarte, H.O.; Gomes, J.; Machado, J.C.; Reis, C.A. Gastric cancer: Basic aspects. Helicobacter 2018, 23 (Suppl. S1), e12523. [Google Scholar] [CrossRef]
- Perkel, J.M. Visiting “noncodarnia”. Biotechniques 2013, 54, 301, 303–304. [Google Scholar] [CrossRef]
- Khalil, A.M.; Guttman, M.; Huarte, M.; Garber, M.; Raj, A.; Rivea Morales, D.; Thomas, K.; Presser, A.; Bernstein, B.E.; van Oudenaarden, A.; et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. USA 2009, 106, 11667–11672. [Google Scholar] [CrossRef]
- Hung, T.; Chang, H.Y. Long noncoding RNA in genome regulation: Prospects and mechanisms. RNA Biol. 2010, 7, 582–585. [Google Scholar] [CrossRef]
- Wilusz, J.E.; Sunwoo, H.; Spector, D.L. Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev. 2009, 23, 1494–1504. [Google Scholar] [CrossRef]
- Zhao, J.; Liu, Y.; Huang, G.; Cui, P.; Zhang, W.; Zhang, Y. Long non-coding RNAs in gastric cancer: Versatile mechanisms and potential for clinical translation. Am. J. Cancer Res. 2015, 5, 907–927. [Google Scholar]
- Gibb, E.A.; Brown, C.J.; Lam, W.L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 2011, 10, 38. [Google Scholar] [CrossRef]
- He, J.; Zhu, S.; Liang, X.; Zhang, Q.; Luo, X.; Liu, C.; Song, L. LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol. Biol. Rep. 2021, 48, 1–15. [Google Scholar] [CrossRef]
- Yan, X.; Lei, L.; Li, H.; Cao, M.; Yang, F.; He, S.; Zhang, S.; Teng, Y.; Li, Q.; Xia, C.; et al. Stomach cancer burden in China: Epidemiology and prevention. Chin. J. Cancer Res. Chung-Kuo Yen Cheng Yen Chiu 2023, 35, 81–91. [Google Scholar] [CrossRef]
- Ferreira, R.J.; dos Santos, D.J.; Ferreira, M.J. P-glycoprotein and membrane roles in multidrug resistance. Future Med. Chem. 2015, 7, 929–946. [Google Scholar] [CrossRef]
- Kathawala, R.J.; Gupta, P.; Ashby, C.R., Jr.; Chen, Z.S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother. 2015, 18, 1–17. [Google Scholar] [CrossRef]
- Mellor, H.R.; Callaghan, R. Resistance to chemotherapy in cancer: A complex and integrated cellular response. Pharmacology 2008, 81, 275–300. [Google Scholar] [CrossRef]
- Raguz, S.; Yague, E. Resistance to chemotherapy: New treatments and novel insights into an old problem. Br. J. Cancer 2008, 99, 387–391. [Google Scholar] [CrossRef]
- Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; Lagarde, J.; Lin, W.; Schlesinger, F.; et al. Landscape of transcription in human cells. Nature 2012, 489, 101–108. [Google Scholar] [CrossRef]
- Ponting, C.P.; Oliver, P.L.; Reik, W. Evolution and functions of long noncoding RNAs. Cell 2009, 136, 629–641. [Google Scholar] [CrossRef]
- Mattick, J.S.; Amaral, P.P.; Carninci, P.; Carpenter, S.; Chang, H.Y.; Chen, L.L.; Chen, R.; Dean, C.; Dinger, M.E.; Fitzgerald, K.A.; et al. Long non-coding RNAs: Definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell. Biol. 2023, 24, 430–447. [Google Scholar] [CrossRef]
- Hahne, J.C.; Lampis, A.; Valeri, N. Vault RNAs: Hidden gems in RNA and protein regulation. Cell. Mol. Life Sci. CMLS 2021, 78, 1487–1499. [Google Scholar] [CrossRef]
- Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; Hertel, J.; Hackermuller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316, 1484–1488. [Google Scholar] [CrossRef]
- Affymetrix, E.T.P.; Cold Spring Harbor Laboratory, E.T.P. Post-transcriptional processing generates a diversity of 5′-modified long and short RNAs. Nature 2009, 457, 1028–1032. [Google Scholar] [CrossRef]
- Chothani, S.P.; Adami, E.; Widjaja, A.A.; Langley, S.R.; Viswanathan, S.; Pua, C.J.; Zhihao, N.T.; Harmston, N.; D’agostino, G.; Whiffin, N.; et al. A high-resolution map of human RNA translation. Mol. Cell 2022, 82, 2885–2899.e8. [Google Scholar] [CrossRef]
- Knoll, M.; Lodish, H.F.; Sun, L. Long non-coding RNAs as regulators of the endocrine system. Nat. Rev. Endocrinol. 2015, 11, 151–160. [Google Scholar] [CrossRef]
- Panni, S.; Lovering, R.C.; Porras, P.; Orchard, S. Non-coding RNA regulatory networks. Biochim. Biophys. Acta Gene Regul. Mech. 2020, 1863, 194417. [Google Scholar] [CrossRef]
- Herman, A.B.; Tsitsipatis, D.; Gorospe, M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol. Cell 2022, 82, 2252–2266. [Google Scholar] [CrossRef] [PubMed]
- Katayama, S.; Tomaru, Y.; Kasukawa, T.; Waki, K.; Nakanishi, M.; Nakamura, M.; Nishida, H.; Yap, C.C.; Suzuki, M.; Kawai, J.; et al. Antisense transcription in the mammalian transcriptome. Science 2005, 309, 1564–1566. [Google Scholar] [CrossRef] [PubMed]
- Statello, L.; Guo, C.-J.; Chen, L.-L.; Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 2021, 22, 96–118. [Google Scholar] [CrossRef] [PubMed]
- van Heesch, S.; van Iterson, M.; Jacobi, J.; Boymans, S.; Essers, P.B.; de Bruijn, E.; Hao, W.; MacInnes, A.W.; Cuppen, E.; Simonis, M. Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol. 2014, 15, R6. [Google Scholar] [CrossRef]
- Li, G.; Deng, L.; Huang, N.; Sun, F. The Biological Roles of lncRNAs and Future Prospects in Clinical Application. Diseases 2021, 9, 8. [Google Scholar] [CrossRef]
- Wang, Q.; Chen, C.; Xu, X.; Shu, C.; Cao, C.; Wang, Z.; Fu, Y.; Xu, L.; Xu, K.; Xu, J.; et al. APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. Adv. Sci. 2022, 9, e2201889. [Google Scholar] [CrossRef] [PubMed]
- Ren, N.; Jiang, T.; Wang, C.; Xie, S.; Xing, Y.; Piao, D.; Zhang, T.; Zhu, Y. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis. Aging 2020, 12, 11025–11041. [Google Scholar] [CrossRef] [PubMed]
- Hang, Q.; Sun, R.; Jiang, C.; Li, Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drugs 2015, 26, 632–640. [Google Scholar] [CrossRef] [PubMed]
- Lan, W.G.; Xu, D.H.; Xu, C.; Ding, C.L.; Ning, F.L.; Zhou, Y.L.; Ma, L.B.; Liu, C.M.; Han, X. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol. Rep. 2016, 36, 263–270. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Lou, T.; Yuan, C.; Wang, Y.; Tu, X.; Wang, Y.; Zhang, T. Effects of lncRNA ANRIL-knockdown on the proliferation, apoptosis and cell cycle of gastric cancer cells. Oncol. Lett. 2021, 22, 621. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Zhu, Y.; Han, S.; Chen, M.; Song, P.; Dai, D.; Xu, W.; Jiang, T.; Feng, L.; Shin, V.Y.; et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 2019, 10, 383. [Google Scholar] [CrossRef] [PubMed]
- Fu, T.; Ji, K.; Jin, L.; Zhang, J.; Wu, X.; Ji, X.; Fan, B.; Jia, Z.; Wang, A.; Liu, J.; et al. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2021, 24, 45–59. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Chunyan, Q.; Zhou, Y.; He, Q.; Ma, Y.; Ga, Y.; Wang, X. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 4064–4070. [Google Scholar] [PubMed]
- Wu, X.; Zheng, Y.; Han, B.; Dong, X. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed. Pharmacother. Biomed. Pharmacother. 2018, 99, 832–838. [Google Scholar] [CrossRef]
- Yang, H.; Hu, Y.; Weng, M.; Liu, X.; Wan, P.; Hu, Y.; Ma, M.; Zhang, Y.; Xia, H.; Lv, K. Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer. J. Adv. Res. 2022, 37, 91–106. [Google Scholar] [CrossRef]
- Zhang, J.; Pang, X.; Lei, L.; Zhang, J.; Zhang, X.; Chen, Z.; Zhu, J.; Jiang, Y.; Chen, G.; Wu, Y.; et al. LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression. Aging 2022, 14, 4137–4157. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Chen, Q.; Chen, P.; Liu, C.; Wang, H.; Zhao, L. The lncRNA CRNDE is regulated by E2F6 and sensitizes gastric cancer cells to chemotherapy by inhibiting autophagy. J. Cancer 2022, 13, 3061–3072. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Wang, H.; Yu, J.; Yao, X.; Yang, S.; Li, W.; Xu, L.; Zhao, L. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol. Cancer 2021, 20, 6. [Google Scholar] [CrossRef] [PubMed]
- Xu, Y.D.; Shang, J.; Li, M.; Zhang, Y.Y. LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 2794–2802. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Zhang, L.; Liang, Q.; Wong, C.C.; Chen, H.; Gou, H.; Dong, Y.; Liu, W.; Li, Z.; Ji, J.; et al. DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance. Oncogenesis 2022, 11, 66. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Lin, Z.; He, Y.; Pang, X.; Wang, Y.; Ponnusamy, M.; Ao, X.; Shan, P.; Tariq, M.A.; Li, P.; et al. The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a. Mol. Ther. Nucleic Acids 2018, 12, 405–419. [Google Scholar] [CrossRef]
- Luo, Y.; Zheng, S.; Wu, Q.; Wu, J.; Zhou, R.; Wang, C.; Wu, Z.; Rong, X.; Huang, N.; Sun, L.; et al. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy 2021, 17, 4083–4101. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Li, Q.; Yu, S.; Zhu, C.; Zhang, Z.; Cao, H.; Xu, J. Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem. Biophys. Res. Commun. 2019, 509, 753–762. [Google Scholar] [CrossRef] [PubMed]
- Gui, Z.; Zhao, Z.; Sun, Q.; Shao, G.; Huang, J.; Zhao, W.; Kuang, Y. LncRNA FEZF1-AS1 Promotes Multi-Drug Resistance of Gastric Cancer Cells via Upregulating ATG5. Front. Cell Dev. Biol. 2021, 9, 749129. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.; Xie, M.; Guo, Y.; Yang, Q.; Hu, S.; Li, Z. Long Non-coding RNA FGD5-AS1 Regulates Cancer Cell Proliferation and Chemoresistance in Gastric Cancer through miR-153-3p/CITED2 Axis. Front. Genet. 2020, 11, 715. [Google Scholar] [CrossRef]
- Tong, K.H.; Qian, J. Long non-coding RNA FGD5-AS1 is an inducer of cisplatin chemoresistance in gastric cancer cells by sponging miR-195. J. Biol. Regul. Homeost. Agents 2021, 35, 819–826. [Google Scholar] [CrossRef] [PubMed]
- Wu, Q.; Ma, J.; Wei, J.; Meng, W.; Wang, Y.; Shi, M. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway. Mol. Oncol. 2021, 15, 299–316. [Google Scholar] [CrossRef] [PubMed]
- Zhang, N.; Wang, A.Y.; Wang, X.K.; Sun, X.M.; Xue, H.Z. GAS5 is downregulated in gastric cancer cells by promoter hypermethylation and regulates adriamycin sensitivity. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 3199–3205. [Google Scholar] [PubMed]
- Hu, J.; Huang, L.; Ding, Q.; Lv, J.; Chen, Z. Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway. Cell Biol. Int. 2022, 46, 173–184. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Liu, B.; Chen, Z.; Li, G.; Zhang, Z. MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and chemo-resistance of gastric cancer. Cell Death Dis. 2020, 11, 233. [Google Scholar] [CrossRef] [PubMed]
- Liang, L.; Kang, H.; Jia, J. HCP5 contributes to cisplatin resistance in gastric cancer through miR-128/HMGA2 axis. Cell Cycle 2021, 20, 1080–1090. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Wang, H. HCP5 Promotes Proliferation and Contributes to Cisplatin Resistance in Gastric Cancer through miR-519d/HMGA1 Axis. Cancer Manag. Res. 2021, 13, 787–794. [Google Scholar] [CrossRef] [PubMed]
- Qiao, X.L.; Zhong, Z.L.; Dong, Y.; Gao, F. LncRNA HMGA1P4 promotes cisplatin-resistance in gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 8830–8836. [Google Scholar] [CrossRef] [PubMed]
- Jiang, L.; Zhang, Y.; Su, P.; Ma, Z.; Ye, X.; Kang, W.; Liu, Y.; Yu, J. Long non-coding RNA HNF1A-AS1 induces 5-FU resistance of gastric cancer through miR-30b-5p/EIF5A2 pathway. Transl. Oncol. 2022, 18, 101351. [Google Scholar] [CrossRef]
- Ma, T.; Wang, R.P.; Zou, X. Dioscin inhibits gastric tumor growth through regulating the expression level of lncRNA HOTAIR. BMC Complement. Altern. Med. 2016, 16, 383. [Google Scholar] [CrossRef]
- Yan, J.; Dang, Y.; Liu, S.; Zhang, Y.; Zhang, G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2016, 37, 16345–16355. [Google Scholar] [CrossRef] [PubMed]
- Cheng, C.; Qin, Y.; Zhi, Q.; Wang, J.; Qin, C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int. J. Biol. Macromol. 2018, 107, 2620–2629. [Google Scholar] [CrossRef] [PubMed]
- Jia, J.; Zhan, D.; Li, J.; Li, Z.; Li, H.; Qian, J. The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. J. Cell. Mol. Med. 2019, 23, 656–669. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Lu, X.; Ma, W.; Xiao, Y.; Wei, C.; Yuan, X.; Wu, Y.; Wang, Y.; Xiong, Y.; Yu, X.; et al. Dampening HOTAIR sensitizes the gastric cancer cells to oxaliplatin through miR-195-5p and ABCG2 pathway. J Cell. Mol. Med. 2023, 27, 3591–3600. [Google Scholar] [CrossRef]
- Wang, J.; Lv, B.; Su, Y.; Wang, X.; Bu, J.; Yao, L. Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis. OncoTargets Ther. 2019, 12, 11325–11338. [Google Scholar] [CrossRef]
- Zhang, Y.; Song, X.; Wang, X.; Hu, J.; Jiang, L. Silencing of LncRNA HULC Enhances Chemotherapy Induced Apoptosis in Human Gastric Cancer. J. Med. Biochem. 2016, 35, 137–143. [Google Scholar] [CrossRef]
- Xin, L.; Zhou, Q.; Yuan, Y.W.; Zhou, L.Q.; Liu, L.; Li, S.H.; Liu, C. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy. J. Cancer Res. Clin. Oncol. 2019, 145, 2507–2517. [Google Scholar] [CrossRef] [PubMed]
- Jiang, X.; Ding, W.; Shen, W.; Jin, J. H19/miR-152-3p/TCF4 axis increases chemosensitivity of gastric cancer cells through suppression of epithelial-mesenchymal transition. Transl. Cancer Res. 2020, 9, 3915–3925. [Google Scholar] [CrossRef]
- Jiang, H.; Hu, K.; Xia, Y.; Liang, L.; Zhu, X. Long Noncoding RNA KLF3-AS1 Acts as an Endogenous RNA of miR-223 to Attenuate Gastric Cancer Progression and Chemoresistance. Front. Oncol. 2021, 11, 704339. [Google Scholar] [CrossRef]
- Han, Y.; Ye, J.; Wu, D.; Wu, P.; Chen, Z.; Chen, J.; Gao, S.; Huang, J. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer 2014, 14, 932. [Google Scholar] [CrossRef]
- Song, Z.; Jia, N.; Li, W.; Zhang, X.Y. LINC01572 Regulates Cisplatin Resistance in Gastric Cancer Cells by Mediating miR-497-5p. OncoTargets Ther. 2020, 13, 10877–10887. [Google Scholar] [CrossRef]
- Zhang, C.; Kang, T.; Wang, X.; Wang, J.; Liu, L.; Zhang, J.; Liu, X.; Li, R.; Wang, J.; Zhang, J. LINC-PINT suppresses cisplatin resistance in gastric cancer by inhibiting autophagy activation via epigenetic silencing of ATG5 by EZH2. Front. Pharmacol. 2022, 13, 968223. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Dai, X.; Zhao, X.; Wang, J.; Dou, J.; Zhuang, H.; Chen, N.; Zhao, H. MiR-874-3p represses the migration and invasion yet promotes the apoptosis and cisplatin sensitivity via being sponged by long intergenic non-coding RNA 00922 (LINC00922) and targeting Glycerophosphodiester Phosphodiesterase Domain Containing 5 (GDPD5) in gastric cancer cells. Bioengineered 2022, 13, 7082–7104. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Y.; Zhou, B.; Hu, X.; Ying, S.; Zhou, Q.; Xu, W.; Feng, L.; Hou, T.; Wang, X.; Zhu, L.; et al. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. Clin. Transl. Med. 2022, 12, e703. [Google Scholar] [CrossRef] [PubMed]
- He, W.; Liang, B.; Wang, C.; Li, S.; Zhao, Y.; Huang, Q.; Liu, Z.; Yao, Z.; Wu, Q.; Liao, W.; et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 2019, 38, 4637–4654. [Google Scholar] [CrossRef] [PubMed]
- YiRen, H.; YingCong, Y.; Sunwu, Y.; Keqin, L.; Xiaochun, T.; Senrui, C.; Ende, C.; XiZhou, L.; Yanfan, C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol. Cancer 2017, 16, 174. [Google Scholar] [CrossRef] [PubMed]
- Xi, Z.; Si, J.; Nan, J. LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int. J. Oncol. 2019, 54, 239–248. [Google Scholar] [CrossRef]
- Xu, W.; Ding, M.; Wang, B.; Cai, Y.; Guo, C.; Yuan, C. Molecular Mechanism of the Canonical Oncogenic lncRNA MALAT1 in Gastric. Curr Med Chem. 2021, 28, 8800–8809. [Google Scholar] [CrossRef] [PubMed]
- Dai, Q.; Zhang, T.; Li, C. LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway. Cancer Manag. Res. 2020, 12, 1929–1939. [Google Scholar] [CrossRef]
- Zhang, Y.F.; Li, C.S.; Zhou, Y.; Lu, X.H. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. Life Sci. 2020, 244, 117280. [Google Scholar] [CrossRef]
- Zhang, Z.; Li, M.; Zhang, Z. lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p. OncoTargets Ther. 2020, 13, 1343–1354. [Google Scholar] [CrossRef]
- Wang, Y.; Zhang, D.; Wu, K.; Zhao, Q.; Nie, Y.; Fan, D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol. Cell. Biol. 2014, 34, 3182–3193. [Google Scholar] [CrossRef] [PubMed]
- Xu, H.F.; Shi, D.M.; Zhu, X.Q. A study of effect of lncRNA MVIH on sensitivity of gastric cancer cells to gemcitabine. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 9651–9659. [Google Scholar] [CrossRef]
- Zhang, J.; Zhao, B.; Chen, X.; Wang, Z.; Xu, H.; Huang, B. Silence of Long Noncoding RNA NEAT1 Inhibits Malignant Biological Behaviors and Chemotherapy Resistance in Gastric Cancer. Pathol. Oncol. Res. POR 2018, 24, 109–113. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Yu, Z.; Wang, J.; Shen, Y.; Qiu, J.; Zhuang, Z. LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a. Cancer Med. 2020, 9, 9499–9510. [Google Scholar] [CrossRef]
- Liu, J.; Ben, Q.; Lu, E.; He, X.; Yang, X.; Ma, J.; Zhang, W.; Wang, Z.; Liu, T.; Zhang, J.; et al. Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer. Cell Death Dis. 2018, 9, 168. [Google Scholar] [CrossRef] [PubMed]
- Ma, Z.; Liu, G.; Hao, S.; Zhao, T.; Chang, W.; Wang, J.; Ren, H.; Zhao, X. PITPNA-AS1/miR-98-5p to Mediate the Cisplatin Resistance of Gastric Cancer. J. Oncol. 2022, 2022, 7981711. [Google Scholar] [CrossRef]
- Zhang, X.W.; Bu, P.; Liu, L.; Zhang, X.Z.; Li, J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem. Biophys. Res. Commun. 2015, 462, 227–232. [Google Scholar] [CrossRef]
- Du, P.; Hu, C.; Qin, Y.; Zhao, J.; Patel, R.; Fu, Y.; Zhu, M.; Zhang, W.; Huang, G. LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer. J. Oncol. 2019, 2019, 9325407. [Google Scholar] [CrossRef]
- Wu, C.; Hu, Y.; Ning, Y.; Zhao, A.; Zhang, G.; Yan, L. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer. Cancer Biother. Radiopharm. 2020, 35, 741–752. [Google Scholar] [CrossRef]
- Xiao, Y.F.; Li, B.S.; Liu, J.J.; Wang, S.M.; Liu, J.; Yang, H.; Hu, Y.Y.; Gong, C.L.; Li, J.L.; Yang, S.M. Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy. Clin. Transl. Med. 2022, 12, e691. [Google Scholar] [CrossRef]
- Li, M.; Zhang, Y.Y.; Shang, J.; Xu, Y.D. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 4185–4191. [Google Scholar] [CrossRef]
- Mei, J.; Liu, G.; Li, R.; Xiao, P.; Yang, D.; Bai, H.; Hao, Y. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis. Biosci. Rep. 2021, 41, BSR20211885. [Google Scholar] [CrossRef]
- Zhang, T.; Beeharry, M.K.; Zheng, Y.; Wang, Z.; Li, J.; Zhu, Z.; Li, C. Long Noncoding RNA SNHG12 Promotes Gastric Cancer Proliferation by Binding to HuR and Stabilizing YWHAZ Expression through the AKT/GSK-3β Pathway. Front. Oncol. 2021, 11, 645832. [Google Scholar] [CrossRef]
- Fisher, L. Expression of concern: Upregulation of lncRNA SUMO1P3 promotes proliferation, invasion and drug resistance in gastric cancer through interacting with the CNBP protein. RSC Adv. 2022, 12, 4572. [Google Scholar] [CrossRef]
- Song, H.; Xu, Y.; Shi, L.; Xu, T.; Fan, R.; Cao, M.; Xu, W.; Song, J. LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability. Biomed. Pharmacother. Biomed. Pharmacother. 2018, 108, 338–346. [Google Scholar] [CrossRef]
- Shang, C.; Guo, Y.; Zhang, J.; Huang, B. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemother. Pharmacol. 2016, 77, 1061–1067. [Google Scholar] [CrossRef]
- Fang, Q.; Chen, X.; Zhi, X. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016, 22, 3506–3513. [Google Scholar] [CrossRef]
- Dai, Q.; Zhang, T.; Pan, J.; Li, C. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J. Cancer 2020, 11, 3882–3892. [Google Scholar] [CrossRef]
- Cheng, H.; Sharen, G.; Wang, Z.; Zhou, J. LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-mediated Apoptosis via miR-513a-3p in Human Gastric Cancer. Cancer Manag. Res. 2021, 13, 367–377. [Google Scholar] [CrossRef]
- Xu, W.; He, L.; Li, Y.; Tan, Y.; Zhang, F.; Xu, H. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/β-catenin signaling in gastric cancer cells. Biosci. Biotechnol. Biochem. 2018, 82, 456–465. [Google Scholar] [CrossRef]
- Gupta, G.P.; Massague, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679–695. [Google Scholar] [CrossRef]
- Shi, Z.; Wei, Q.; She, J. MicroRNAs in gastric cancer metastasis. Crit. Rev. Eukaryot. Gene Expr. 2014, 24, 39–53. [Google Scholar] [CrossRef]
- Shen, X.H.; Qi, P.; Du, X. Long non-coding RNAs in cancer invasion and metastasis. Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc 2015, 28, 4–13. [Google Scholar] [CrossRef]
- Al Bitar, S.; El-Sabban, M.; Doughan, S.; Abou-Kheir, W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J. Gastroenterol. 2023, 29, 1395–1426. [Google Scholar] [CrossRef]
- Yang, K.D.; Wang, Y.; Zhang, F.; Li, Q.L.; Luo, B.H.; Feng, D.Y.; Zeng, Z.J. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer. Mol. Cell. Biochem. 2022, 477, 2493–2505. [Google Scholar] [CrossRef]
- Xu, J.; Xu, Y.; Ye, G.; Qiu, J. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J. Chemother. 2022, 35, 527–538. [Google Scholar] [CrossRef]
- Wei, S.C.; Duffy, C.R.; Allison, J.P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018, 8, 1069–1086. [Google Scholar] [CrossRef]
- Park, Y.J.; Kuen, D.S.; Chung, Y. Future prospects of immune checkpoint blockade in cancer: From response prediction to overcoming resistance. Exp. Mol. Med. 2018, 50, 1–13. [Google Scholar] [CrossRef]
- Muro, K.; Chung, H.C.; Shankaran, V.; Geva, R.; Catenacci, D.; Gupta, S.; Eder, J.P.; Golan, T.; Le, D.T.; Burtness, B.; et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet. Oncol. 2016, 17, 717–726. [Google Scholar] [CrossRef]
- Kang, Y.K.; Boku, N.; Satoh, T.; Ryu, M.H.; Chao, Y.; Kato, K.; Chung, H.C.; Chen, J.S.; Muro, K.; Kang, W.K.; et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 390, 2461–2471. [Google Scholar] [CrossRef]
- Monteiro, J.; Fodde, R. Cancer stemness and metastasis: Therapeutic consequences and perspectives. Eur. J. Cancer 2010, 46, 1198–1203. [Google Scholar] [CrossRef]
- Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [Google Scholar] [CrossRef]
- Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3, 362–374. [Google Scholar] [CrossRef]
- Tsuji, T.; Ibaragi, S.; Hu, G.F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009, 69, 7135–7139. [Google Scholar] [CrossRef]
- Evan, G.I.; Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411, 342–348. [Google Scholar] [CrossRef]
- Harbour, J.W.; Dean, D.C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev. 2000, 14, 2393–2409. [Google Scholar] [CrossRef]
- Xiao, L.; Wang, W.; Zhao, J.; Xu, H.; Li, S.; Yang, X. lncRNA MALAT1 promotes cell proliferation and invasion by regulating the miR-101/EZH2 axis in oral squamous cell carcinoma. Oncol. Lett. 2020, 20, 164. [Google Scholar] [CrossRef]
- Neophytou, C.M.; Trougakos, I.P.; Erin, N.; Papageorgis, P. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers 2021, 13, 4363. [Google Scholar] [CrossRef]
- Danial, N.N. BCL-2 family proteins: Critical checkpoints of apoptotic cell death. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 7254–7263. [Google Scholar] [CrossRef]
- Mita, A.C.; Mita, M.M.; Nawrocki, S.T.; Giles, F.J. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 5000–5005. [Google Scholar] [CrossRef]
- Kruiswijk, F.; Labuschagne, C.F.; Vousden, K.H. p53 in survival, death and metabolic health: A lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 2015, 16, 393–405. [Google Scholar] [CrossRef] [PubMed]
- Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. Cancers 2014, 6, 1769–1792. [Google Scholar] [CrossRef] [PubMed]
- Shang, C.; Sun, L.; Zhang, J.; Zhao, B.; Chen, X.; Xu, H.; Huang, B. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget 2017, 8, 15393–15398. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Wang, Q.; Xu, G.; Meng, N.; Huang, X.; Jiang, Z.; Chen, C.; Zhang, Y.; Chen, J.; Li, A.; et al. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells. RNA Biol. 2020, 17, 1576–1589. [Google Scholar] [CrossRef]
- Ichimiya, T.; Yamakawa, T.; Hirano, T.; Yokoyama, Y.; Hayashi, Y.; Hirayama, D.; Wagatsuma, K.; Itoi, T.; Nakase, H. Autophagy and Autophagy-Related Diseases: A Review. Int. J. Mol. Sci. 2020, 21, 8974. [Google Scholar] [CrossRef]
- Qin, Y.; Ashrafizadeh, M.; Mongiardini, V.; Grimaldi, B.; Crea, F.; Rietdorf, K.; Gyorffy, B.; Klionsky, D.J.; Ren, J.; Zhang, W.; et al. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence. Cancer Lett. 2023, 570, 216307. [Google Scholar] [CrossRef] [PubMed]
- Ayala, A.; Munoz, M.F.; Arguelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Med. Cell. Longev. 2014, 2014, 360438. [Google Scholar] [CrossRef]
- Xiao, S.; Liu, X.; Yuan, L.; Wang, F. A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Therapeutic Response of Gastric Cancer. Front. Cell Dev. Biol. 2021, 9, 736682. [Google Scholar] [CrossRef]
- Guo, Y.; Yue, P.; Wang, Y.; Chen, G.; Li, Y. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis. Biomed. Pharmacother. Biomed. Pharmacother. 2019, 118, 109255. [Google Scholar] [CrossRef]
- Liu, H.; Zhang, Z.; Han, Y.; Fan, A.; Liu, H.; Zhang, X.; Liu, Y.; Zhang, R.; Liu, W.; Lu, Y.; et al. The FENDRR/FOXC2 Axis Contributes to Multidrug Resistance in Gastric Cancer and Correlates with Poor Prognosis. Front. Oncol. 2021, 11, 634579. [Google Scholar] [CrossRef] [PubMed]
- Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell 2011, 146, 353–358. [Google Scholar] [CrossRef] [PubMed]
- Arancio, W.; Pizzolanti, G.; Genovese, S.I.; Baiamonte, C.; Giordano, C. Competing endogenous RNA and interactome bioinformatic analyses on human telomerase. Rejuvenation Res. 2014, 17, 161–167. [Google Scholar] [CrossRef]
- Nai, A.; Zeng, H.; Wu, Q.; He, Z.; Zeng, S.; Bashir, S.; Ma, F.; He, J.; Wan, W.; Xu, M. lncRNA/miR-29c-Mediated High Expression of LOX Can Influence the Immune Status and Chemosensitivity and Can Forecast the Poor Prognosis of Gastric Cancer. Front. Cell Dev. Biol. 2021, 9, 760470. [Google Scholar] [CrossRef]
- Kawaguchi, K.; Han, Q.; Li, S.; Tan, Y.; Igarashi, K.; Murakami, T.; Unno, M.; Hoffman, R.M. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. Cells 2019, 8, 410. [Google Scholar] [CrossRef] [PubMed]
- Tsai, S.Y.; Ardelt, B.; Hsieh, T.C.; Darzynkiewicz, Z.; Shogen, K.; Wu, J.M. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int. J. Oncol. 2004, 25, 1745–1752. [Google Scholar] [CrossRef]
- Pei, L.J.; Sun, P.J.; Ma, K.; Guo, Y.Y.; Wang, L.Y.; Liu, F.D. LncRNA-SNHG7 interferes with miR-34a to de-sensitize gastric cancer cells to cisplatin. Cancer Biomark. Sect. A Dis. Markers 2021, 30, 127–137. [Google Scholar] [CrossRef]
- Ding, Y.; Gao, S.; Zheng, J.; Chen, X. Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism. Cancer Metab. 2022, 10, 20. [Google Scholar] [CrossRef]
- Dang, S.; Malik, A.; Chen, J.; Qu, J.; Yin, K.; Cui, L.; Gu, M. LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer through Targeting miR141/PD-L1. OncoTargets Ther. 2020, 13, 8547–8556. [Google Scholar] [CrossRef]
- Li, Y.; Lv, S.; Ning, H.; Li, K.; Zhou, X.; Xv, H.; Wen, H. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed. Pharmacother. Biomed. Pharmacother. 2018, 108, 1775–1782. [Google Scholar] [CrossRef]
- Fortini, M.E. Notch signaling: The core pathway and its posttranslational regulation. Dev. Cell 2009, 16, 633–647. [Google Scholar] [CrossRef] [PubMed]
- Ropero, S.; Fraga, M.F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M.F.; et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38, 566–569. [Google Scholar] [CrossRef] [PubMed]
- Ren, H.; Tang, L. HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway. Neoplasma 2021, 68, 1043–1051. [Google Scholar] [CrossRef] [PubMed]
- Huang, G.; Cai, G.; Hu, D.; Li, J.; Xu, Q.; Chen, Z.; Xu, B. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition. Cell. Oncol. 2022, 45, 1329–1346. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.L.; Bi, X.W.; Liu, P.P.; Lei, D.X.; Wang, Y.; Li, Z.M.; Jiang, W.Q.; Xia, Y. Expressions and prognostic values of the E2F transcription factors in human breast carcinoma. Cancer Manag. Res. 2018, 10, 3521–3532. [Google Scholar] [CrossRef] [PubMed]
- Bridges, M.C.; Daulagala, A.C.; Kourtidis, A. LNCcation: lncRNA localization and function. J. Cell Biol. 2021, 220, e202009045. [Google Scholar] [CrossRef] [PubMed]
- Duan, R.; Du, W.; Guo, W. EZH2: A novel target for cancer treatment. J. Hematol. Oncol. 2020, 13, 104. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Ma, X.; Yang, D.; Suo, Z.; Dai, R.; Liu, C. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. J. Cell. Biochem. 2020, 121, 1353–1361. [Google Scholar] [CrossRef]
- Xin, L.; Zhou, L.Q.; Liu, C.; Zeng, F.; Yuan, Y.W.; Zhou, Q.; Li, S.H.; Wu, Y.; Wang, J.L.; Wu, D.Z.; et al. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer. EMBO Rep. 2021, 22, e52124. [Google Scholar] [CrossRef]
- Zhu, W.; Tan, L.; Ma, T.; Yin, Z.; Gao, J. Long noncoding RNA SNHG8 promotes chemoresistance in gastric cancer via binding with hnRNPA1 and stabilizing TROY expression. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2022, 54, 1573–1582. [Google Scholar] [CrossRef]
- Bai, L.; Dong, K.; Tong, D.; Shi, X.; Wei, S.; Cai, Y. lncRNA HIT000218960 enhances resistance to 5-fluorouracil by promoting HMGA2 and activating the AKT/mTOR/P70S6K pathway in gastric cancer cells. Exp. Ther. Med. 2022, 24, 527. [Google Scholar] [CrossRef] [PubMed]
- Tan, J.N.; Zhou, S.N.; Zhang, W.; Yang, B.; Zhong, G.Y.; Huang, J.; Hu, H.; Han, F.H.; Luo, M.L. Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer. Cancer Sci. 2022, 113, 3055–3070. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Garcia, B.A. Comprehensive Catalog of Currently Documented Histone Modifications. Cold Spring Harb. Perspect. Biol. 2015, 7, a025064. [Google Scholar] [CrossRef] [PubMed]
- Cao, R.; Zhang, Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 2004, 14, 155–164. [Google Scholar] [CrossRef] [PubMed]
- Cao, R.; Wang, L.; Wang, H.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R.S.; Zhang, Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298, 1039–1043. [Google Scholar] [CrossRef] [PubMed]
- Turner, B.M. Histone acetylation and an epigenetic code. BioEssays News Rev. Mol. Cell. Dev. Biol. 2000, 22, 836–845. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef]
- Glickman, M.H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 2002, 82, 373–428. [Google Scholar] [CrossRef]
- Zhou, Y.; Fan, R.G.; Qin, C.L.; Jia, J.; Wu, X.D.; Zha, W.Z. LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma. Genomics 2019, 111, 1862–1872. [Google Scholar] [CrossRef]
- Zhao, L.; Han, T.; Li, Y.; Sun, J.; Zhang, S.; Liu, Y.; Shan, B.; Zheng, D.; Shi, J. The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2017, 31, 893–903. [Google Scholar] [CrossRef]
- Narayanankutty, A. PI3K/Akt/mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. Curr. Drug Targets 2019, 20, 1217–1226. [Google Scholar] [CrossRef] [PubMed]
- Scheidereit, C. IkappaB kinase complexes: Gateways to NF-kappaB activation and transcription. Oncogene 2006, 25, 6685–6705. [Google Scholar] [CrossRef] [PubMed]
- Silverman, N.; Maniatis, T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001, 15, 2321–2342. [Google Scholar] [CrossRef] [PubMed]
- Kusunoki, T.; Sugai, M.; Gonda, H.; Nambu, Y.; Nagata-Nakajima, N.; Katakai, T.; Kusunoki, M.; Sakamoto, A.; Tokuhisa, T.; Nakahata, T.; et al. CpG inhibits IgE class switch recombination through suppression of NF kappa B activity, but not through Id2 or Bcl6. Biochem. Biophys. Res. Commun. 2005, 328, 499–506. [Google Scholar] [CrossRef] [PubMed]
- Lake, D.; Correa, S.A.; Muller, J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell. Mol. Life Sci. CMLS 2016, 73, 4397–4413. [Google Scholar] [CrossRef] [PubMed]
- Miao, X.; Liu, Y.; Fan, Y.; Wang, G.; Zhu, H. LncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell through the ERK1/2 Pathway. Cancer Manag. Res. 2021, 13, 287–296. [Google Scholar] [CrossRef] [PubMed]
- Zhou, M.; Dong, J.; Huang, J.; Ye, W.; Zheng, Z.; Huang, K.; Pan, Y.; Cen, J.; Liang, Y.; Shu, G.; et al. Chitosan-Gelatin-EGCG Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5-FU Resistance in Gastric Cancer. Adv. Sci. 2022, 9, e2105077. [Google Scholar] [CrossRef] [PubMed]
- Fukumura, D.; Jain, R.K. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007, 101, 937–949. [Google Scholar] [CrossRef]
- Justus, C.R.; Dong, L.; Yang, L.V. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front. Physiol. 2013, 4, 354. [Google Scholar] [CrossRef]
- Reina-Campos, M.; Moscat, J.; Diaz-Meco, M. Metabolism shapes the tumor microenvironment. Curr. Opin. Cell Biol. 2017, 48, 47–53. [Google Scholar] [CrossRef]
- Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891–899. [Google Scholar] [CrossRef]
- Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11, 85–95. [Google Scholar] [CrossRef] [PubMed]
- Slack, F.J.; Chinnaiyan, A.M. The Role of Non-coding RNAs in Oncology. Cell 2019, 179, 1033–1055. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.; Liu, F.; Wang, Y.; Qu, L.; Lin, A. LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling. Cancer Lett. 2022, 543, 215798. [Google Scholar] [CrossRef]
- Luo, X.; Cheng, C.; Tan, Z.; Li, N.; Tang, M.; Yang, L.; Cao, Y. Emerging roles of lipid metabolism in cancer metastasis. Mol. Cancer 2017, 16, 76. [Google Scholar] [CrossRef] [PubMed]
- Kastaniotis, A.J.; Autio, K.J.; Keratar, J.M.; Monteuuis, G.; Makela, A.M.; Nair, R.R.; Pietikainen, L.P.; Shvetsova, A.; Chen, Z.; Hiltunen, J.K. Mitochondrial fatty acid synthesis, fatty acids and mitochondrial physiology. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2017, 1862, 39–48. [Google Scholar] [CrossRef] [PubMed]
- Hsu, P.P.; Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134, 703–707. [Google Scholar] [CrossRef]
- Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306. [Google Scholar] [CrossRef] [PubMed]
- Binnewies, M.; Roberts, E.W.; Kersten, K.; Chan, V.; Fearon, D.F.; Merad, M.; Coussens, L.M.; Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Hedrick, C.C.; et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550. [Google Scholar] [CrossRef]
- Liu, Z.; Han, C.; Fu, Y.X. Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cell Mol. Immunol. 2020, 17, 13–26. [Google Scholar] [CrossRef]
- Hu, Q.; Ye, Y.; Chan, L.C.; Li, Y.; Liang, K.; Lin, A.; Egranov, S.D.; Zhang, Y.; Xia, W.; Gong, J.; et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat. Immunol. 2019, 20, 835–851. [Google Scholar] [CrossRef]
- Agata, Y.; Kawasaki, A.; Nishimura, H.; Ishida, Y.; Tsubata, T.; Yagita, H.; Honjo, T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8, 765–772. [Google Scholar] [CrossRef]
- Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677–704. [Google Scholar] [CrossRef]
- Ruf, M.; Moch, H.; Schraml, P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int. J. Cancer 2016, 139, 396–403. [Google Scholar] [CrossRef] [PubMed]
- Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141, 39–51. [Google Scholar] [CrossRef] [PubMed]
- Yamaguchi, T.; Fushida, S.; Yamamoto, Y.; Tsukada, T.; Kinoshita, J.; Oyama, K.; Miyashita, T.; Tajima, H.; Ninomiya, I.; Munesue, S.; et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2016, 19, 1052–1065. [Google Scholar] [CrossRef]
- Tenti, P.; Vannucci, L. Lysyl oxidases: Linking structures and immunity in the tumor microenvironment. Cancer Immunol. Immunother. CII 2020, 69, 223–235. [Google Scholar] [CrossRef]
- Whiteside, T.L. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin. Immunol. 2018, 35, 69–79. [Google Scholar] [CrossRef] [PubMed]
- Ding, J.; Li, D.; Gong, M.; Wang, J.; Huang, X.; Wu, T.; Wang, C. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. OncoTargets Ther. 2014, 7, 1625–1630. [Google Scholar] [CrossRef]
- Chen, D.; Wang, M.; Jiang, X.; Xiong, Z. Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: From gastric adenocarcinoma to pan-cancers. Discover. Oncol. 2022, 13, 24. [Google Scholar] [CrossRef]
- Song, Q.; Lv, X.; Ru, Y.; Dong, J.; Chang, R.; Wu, D.; Chen, L.; Wang, X.; Guo, X. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study. EBioMedicine 2022, 78, 103971. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, L.; Tu, Y.; Feng, Z.; Li, Z.; Cao, Y.; Li, Y. A DCS-related lncRNA signature predicts the prognosis and chemotherapeutic response of patients with gastric cancer. Biosci. Rep. 2022, 42, BSR20220989. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Chen, X.; Jiang, F.; Shen, Y.; Fang, F.; Li, Q.; Yang, C.; Dong, Y.; Shen, X. A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity. Front. Genet. 2022, 13, 939439. [Google Scholar] [CrossRef]
- Wang, Z.; Cao, L.; Zhou, S.; Lyu, J.; Gao, Y.; Yang, R. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration. Front. Immunol. 2022, 13, 854785. [Google Scholar] [CrossRef] [PubMed]
- Guo, C.; Liu, Z.; Yu, Y.; Liu, S.; Ma, K.; Ge, X.; Xing, Z.; Lu, T.; Weng, S.; Wang, L.; et al. Integrated Analysis of Multi-Omics Alteration, Immune Profile, and Pharmacological Landscape of Pyroptosis-Derived lncRNA Pairs in Gastric Cancer. Front. Cell Dev. Biol. 2022, 10, 816153. [Google Scholar] [CrossRef]
- Xu, T.; Gu, H.; Zhang, C.; Zhang, W.; Liang, X.; Cheng, X. A Novel Risk Model Identified Based on Pyroptosis-Related lncRNA Predicts Overall Survival and Associates with the Immune Landscape of GC Patients. Front. Genet. 2022, 13, 843538. [Google Scholar] [CrossRef]
- Jiang, Q.; Chen, H.; Tang, Z.; Sun, J.; Ruan, Y.; Liu, F.; Sun, Y. Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer. BMC Cancer 2021, 21, 1067. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Q.; Chen, L.; Chen, H.; Tang, Z.; Liu, F.; Sun, Y. Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients. Front. Cell Dev. Biol. 2021, 9, 739509. [Google Scholar] [CrossRef]
- Song, X.; Hou, L.; Zhao, Y.; Guan, Q.; Li, Z. Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer. Front. Pharmacol. 2022, 13, 1039499. [Google Scholar] [CrossRef]
- Wang, Y.; Liu, K.; Shen, K.; Xiao, J.; Zhou, X.; Cheng, Q.; Hu, L.; Fan, H.; Ni, P.; Xu, Z.; et al. A novel risk model construction and immune landscape analysis of gastric cancer based on cuproptosis-related long noncoding RNAs. Front. Oncol. 2022, 12, 1015235. [Google Scholar] [CrossRef]
- Sun, J.; Jiang, Q.; Chen, H.; Zhang, Q.; Zhao, J.; Li, H.; Wang, X.; Fang, Y.; Ruan, Y.; Sun, Y. Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer. Ann. Transl. Med. 2021, 9, 1326. [Google Scholar] [CrossRef] [PubMed]
- Yi, C.; Zhang, X.; Chen, X.; Huang, B.; Song, J.; Ma, M.; Yuan, X.; Zhang, C. A novel 8-genome instability-associated lncRNAs signature predicting prognosis and drug sensitivity in gastric cancer. Int. J. Immunopathol. Pharmacol. 2022, 36, 3946320221103195. [Google Scholar] [CrossRef] [PubMed]
- Gao, L.; Xue, J.; Liu, X.; Cao, L.; Wang, R.; Lei, L. A risk model based on autophagy-related lncRNAs for predicting prognosis and efficacy of immunotherapy and chemotherapy in gastric cancer patients. Aging 2021, 13, 25453–25465. [Google Scholar] [CrossRef]
- Yuan, M.; Jia, Y.; Xing, Y.; Wang, Y.; Liu, Y.; Liu, X.; Liu, D. Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients. Front. Genet. 2022, 13, 965033. [Google Scholar] [CrossRef] [PubMed]
- Felipe, A.V.; de Oliveira, J.; Chang, P.Y.J.; Moraes, A.A.d.F.S.; da Silva, T.D.; Tucci-Viegas, V.M.; Forones, N.M. RNA interference: A promising therapy for gastric cancer. Asian Pac. J. Cancer Prev. 2014, 15, 5509–5515. [Google Scholar] [CrossRef]
- Wang, S.; Chen, W.; Yu, H.; Song, Z.; Li, Q.; Shen, X.; Wu, Y.; Zhu, L.; Ma, Q.; Xing, D. lncRNA ROR Promotes Gastric Cancer Drug Resistance. Cancer Control 2020, 27, 1073274820904694. [Google Scholar] [CrossRef]
- Zhu, Y. Advances in CRISPR/Cas9. BioMed Res. Int. 2022, 2022, 9978571. [Google Scholar] [CrossRef]
- Morin, P.J. Drug resistance and the microenvironment: Nature and nurture. Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother. 2003, 6, 169–172. [Google Scholar] [CrossRef]
LncRNA | Resistance (Sensitivity) | Functions | Refs. |
---|---|---|---|
ABL | paclitaxel, 5-FU | apoptosis | [31] |
ADAMTS9-AS2 | (cisplatin) | proliferation, apoptosis | [32] |
AK022798 | cisplatin | apoptosis | [33] |
ANRIL | cisplatin, 5-FU | proliferation, metastasis, apoptosis | [34,35] |
ARHGAP5-AS | cisplatin, 5-FU, rapamycin, | proliferation, apoptosis | [36] |
doxorubicin, actinomycin D | |||
ASB16-AS1 | cisplatin | proliferation, stemness | [37] |
BCAR4 | cisplatin | stemness | [38] |
BLACAT1 | oxaliplatin | metastasis, apoptosis | [39] |
CBSLR | cisplatin | ferroptosis | [40] |
CRART16 | bevacizumab | proliferation | [41] |
CRNDE | oxaliplatin, 5-FU | apoptosis, autophagy | [42,43] |
DANCR | cisplatin | proliferation, apoptosis | [44] |
DUSP5P1 | oxaliplatin | proliferation, metastasis | [45] |
D63785 | doxorubicin | proliferation, metastasis | [46] |
EIF3J-DT | oxaliplatin, 5-FU | apoptosis, autophagy | [47] |
FAM84B-AS | cisplatin | proliferation, metastasis, apoptosis | [48] |
FEZF1-AS1 | cisplatin, 5-FU | proliferation, autophagy | [49] |
FGD5-AS1 | 5-FU | proliferation | [50,51] |
FOXD1-AS1 | cisplatin | proliferation | [52] |
GAS5 | (adriamycin) | proliferation, apoptosis | [53] |
HAGLR | 5-FU | proliferation | [54] |
HCP5 | oxaliplatin, cisplatin,5-FU | proliferation, apoptosis, stemness | [55,56,57] |
HMGA1P4 | cisplatin | proliferation, apoptosis | [58] |
HNF1A-AS1 | 5-FU | proliferation, metastasis | [59] |
HOTAIR | cisplatin, oxaliplatin | proliferation, metastasis, apoptosis | [60,61,62,63,64] |
HOTTIP | cisplatin | proliferation, metastasis, apoptosis | [65] |
HULC | cisplatin | proliferation, apoptosis, autophagy | [66,67] |
H19 | adriamycin | apoptosis | [68] |
KLF3-AS1 | cisplatin | proliferation, metastasis | [69] |
LEIGC | 5-FU | proliferation, metastasis | [70] |
LINC01572 | cisplatin | autophagy | [71] |
LINC-PINT | cisplatin | proliferation, metastasis, autophagy | [72] |
LINC00922 | cisplatin | proliferation, metastasis, apoptosis | [73] |
LINC00942 | cisplatin | apoptosis, stemness | [74] |
MACC1-AS1 | 5-FU | stemness | [75] |
MALAT1 | cisplatin, oxaliplatin, vincristine | proliferation, metastasis, apoptosis, autophagy, stemness | [76,77,78,79,80,81] |
MRUL | doxorubicin | proliferation, apoptosis | [82] |
MVIH | gemcitabine | proliferation, metastasis, apoptosis | [83] |
NEAT1 | adriamycin | proliferation, metastasis, apoptosis | [84] |
NUTM2A-AS1 | PD-1 | proliferation, metastasis | [85] |
PANDAR | oxaliplatin, 5-FU | proliferation, apoptosis | [86] |
PITPNA-AS1 | cisplatin | proliferation, apoptosis | [87] |
PVT1 | cisplatin, 5-FU | proliferation, metastasis, apoptosis | [88,89,90] |
SLCO1C1 | oxaliplatin | proliferation, metastasis | [91] |
SNHG1 | paclitaxel | metastasis | [54] |
SNHG5 | cisplatin | apoptosis | [92] |
SNHG6 | cisplatin | proliferation, metastasis, apoptosis | [93] |
SNHG12 | oxaliplatin, 5-FU | proliferation | [94] |
ST7-AS1 | cisplatin | proliferation, metastasis, apoptosis | [93] |
SUMO1P3 | cisplatin, 5-FU | proliferation, metastasis | [95] |
THOR | cisplatin | stemness | [96] |
UCA1 | cisplatin, doxorubicin | proliferation, apoptosis | [97,98,99,100] |
ZFAS1 | cisplatin, paclitaxel | proliferation, metastasis, apoptosis | [101] |
LncRNA or Model | LncRNA Name or ID | Functions | Data | Experimental Methods | Clinical Application | Refs. |
---|---|---|---|---|---|---|
A 9-ARlncRNA signature | AL357054.4, AC018682.1, A2M-AS1, AP001107.5, CAPN10-DT, HAND2-AS1, LINC01081, PIK3CD-AS1, ZNF710-AS1 | ARlncRNAs | TCGA | HTS, algorithm | predicting prognosis and efficacy of immunotherapy and chemotherapy | [203] |
A 13-SRlncRNA signature | AC026369.2, AC024267.4, AC017074.1, AC0104695.4, AC016394.3, AC009022.1, AC112484.3, AC005391.1, LINC00941, LINC02532, LINC01614, LINC01943, SMIM25 | SRlncRNAs | TCGA | HTS, algorithm | predicting immunotherapy response | [197] |
A 23-SRlncRNA signature | AP000873.4, AC116158.1, RNF144A-AS1, LINC01094, MAPKAPK5-AS1, AL136115.1, AL391152.1, AC147067.2, AL356215.1, ADAMTS9-AS1, AC011747.1, AL353796.1, AC104695.4, AC087521.1, AC078860.2, AC027682.6, AC104809.2, AC129507.1, AC010768.2, AC026412.3, LINC01614, LINC00519, LINC00449 | SRlncRNAs | TCGA/Zhongshan/IMvigor210 | HTS, algorithm | predicting chemotherapy and immunotherapy response | [198] |
A 6-GIRlncRNA signature | AC010789.1, HOXA10-AS, LINC02678, LINC01150, RHOXF1-AS1, TGFB2-AS1 | GIRlncRNAs | TCGA | HTS, algorithm | predicting immunotherapy response | [201] |
A 17-FRlncRNA signature | AC104260.2, AP000438.1, AL022316.1, AL391152.1, AC021106.3, AC131391.1, AL355001.1, AP000695.1, AP001107.6, AC007391.1, AL021154.1, AC104758.1, FP700111.1, MACORIS, RFS1-IT2, SPATA13-AS1, SCAT8 | FRlncRNAs | TCGA/GEO | HTS, algorithm | predicting prognosis and therapeutic response | [129] |
A 14-PRlncRNA signature | AC074286.1, AC013275.2, C10orf91, CTD-2377D24.6, LINC00607, LINC01094, LINC00607, LINC01588, MMP25-AS1, MLLT4-AS1, RP3-522D1.1, RP11-61A14.1, TUSC8, TRPM2-AS | PRlncRNAs | TCGA/GEO | HTS, algorithm | predicting differential sensitivity to multiple chemotherapeutic agents | [195] |
A CElncRNA-GC1 and AJCC stage | lncRNA-GC1 | MRRlncRNAs | Central data | HTS, algorithm | predicting prognosis and chemotherapy response after surgery | [191] |
A 12-F/CRlncRNA signature | ENSG00000221819.5, ENSG00000230387.2, ENSG00000233262.1, ENSG00000239265.4, ENSG00000241111.1, ENSG00000248279.4, ENSG00000248356.1, ENSG00000249807.1, ENSG00000250303.3, ENSG00000256220.1, ENSG00000265194.1, ENSG00000266957.1 | F/CRlncRNAs | TCGA and literature | HTS, algorithm | predicting chemotherapy response | [199] |
A 3-PRlncRNA signature | AC017076.1, CYMP-AS1, PVT1 | PRlncRNAs | GSEA and literature | HTS, algorithm | predicting immunotherapy and chemotherapy drug sensitivity | [193] |
A 10-CRlncRNA signature | AC016737.1, AL391152.1, AL121748.1, AL512506.1, AC104809.2, AL353804.2, AL353796.1, AL355574.1, LINC01980, TYMSOS | CRlncRNAs | TCGA | HTS, algorithm | predicting prognosis and presenting immune landscape | [200] |
A 4-PRlncRNA signature | HAND2-AS1, LINC01354, PGM5-AS1, RP11-276H19.1 | PRlncRNAs | TCGA | HTS, algorithm | predicting prognosis and immune microenvironment status | [194] |
A 11-PRlncRNA signature | AL353804.1, AC147067.2, AP001318.2, AC018752.1, ACTA2-AS1, AL121772.1, AC005332.4, AC245041.2, HAGLR, RRN3P2, UBL7-AS1 | PRlncRNAs | TCGA | HTS, algorithm | predicting prognosis and immune landscape | [196] |
A 8-GIRlncRNA signature | AC078883.2, AL049838.1, AL359182.1, AL365181.3, LINC01436, LINC01833, LINC01614, RHOXF1-AS1 | GIRlncRNAs | TCGA/GEO | HTS, algorithm | predicting prognosis and immunotherapy response | [202] |
A 7-PLTRlncRNA signature | AC002401.4, AC129507.1, AL513123.1, AL355574.1, AL356417.2, LINC01697, LINC01094 | PLTRlncRNAs | TCGA | HTS, algorithm | predicting prognosis and immunotherapy response | [204] |
A 11-DCSRlncRNA signature | AC007277.1, AC005324.4, AL512506.1, AC068790.7, AC022509.2, AC113139.1, LINC02532, LINC00106, AC005165.1, MIR100HG, UBE2R2-AS1 | DCSRlncRNAs | TCGA/GEO | HTS, algorithm | predicting chemotherapy response and immune infiltration in patients with GC | [192] |
PVT1 | PVT1 | PRRlncRNAs | DE SGC7901/SGC7901P | HTS | predicting lymph node invasion | [189] |
ZFPM2-AS1 | ZFPM2-AS1 | IRlncRNAs | TCGA | HTS, algorithm | predicting survival and reducing the sensitivity to cisplatin | [190] |
LncRNA | Sources | Expression | Prognosis | Refs. |
---|---|---|---|---|
ABL | Microarray (T vs. no-T) | ↑ | TNM(+), OS(+), IPF | [31] |
ADAMTS9-AS2 | Literature search | ↑ | Size(+), lymphatic invasion(+), TNM(+), OS(+) | [32] |
ARHGAP5-AS | Microarray (R-c vs. S-c) | ↑ | Gender(+), TNM(+), OS(+), PFS(+), IPF | [36] |
BCAR4 | Literature search | ↑ | Size(+), Lauren type(+), histological grade(+), lymph node metastasis(+), distant metastasis(+), TNM(+), 3-y RFS(+), IPF | [38] |
CBSLR | Microarray (H vs. no-H) | ↑ | OS(+), DFS(+) | [40] |
CRART16 | Microarray (T vs. no-T) | ↑ | TNM(+), OS(+) | [41] |
CRNDE | Literature search | ↓ | OS(+), DFS(+) | [42] |
DUSP5P1 | CHIP-sequencing | ↑ | TNM(+), OS(+), PFS(+), IPF | [45] |
D63785 | Microarray (T vs. no-T) | ↑ | 3-y OS(+) | [46] |
EIF3J-DT | Microarray (R-c vs. S-c) | ↑ | RFS(+) | [47] |
FAM84B-AS | Microarray (R-t vs. S-t) | ↑ | Differentiation(+), vascular cancer thrombus(+), nerve invasion(+), TNM(+), IPF | [48] |
FEZF1-AS1 | Literature search | ↑ | OS(+) | [49] |
FGD5-AS1 | Size(+), TNM(+) | [51] | ||
HCP5 | Literature search | ↑ | 5-y OS(+) | [56] |
HULC | Literature search | ↑ | 5-y OS(+) | [66] |
LINC-PINT | Literature search | ↓ | Recurrence(+), OS(+) | [72] |
MACC1-AS1 | Literature search | ↑ | TNM(+), DFS(+), OS(+), IPF | [75] |
MALAT1 | Literature search | ↑ | OS(+), DFS(+) | [76] |
TCGA (T vs. no-T) | ↑ | OS(+), IPF | [79] | |
NUTM2A-AS1 | Literature search | ↑ | TMN(+), OS(+) | [85] |
PANDAR | Microarray (T vs. no-T) | ↑ | Size(+), TNM(+), 5-y OS(+), IPF | [86] |
PVT1 | TCGA/GEO (T vs. no-T) | ↑ | TNM(+), OS(+), PFS(+) | [89] |
PITPNA-AS1 | Microarray (T vs. no-T) | ↑ | OS(+) | [87] |
SLCO1C1 | Microarray (T vs. no-T) | ↑ | Size(+), differentiation(+), OS(+) | [91] |
SNHG12 | Literature search | ↑ | TNM(+), OS(+) | [94] |
SUMO1P3 | Literature search | ↑ | TNM(+), OS(+) | [95] |
UCA1 | Microarray (T vs. no-T) | ↑ | Size(+), differentiation(+), Borrman type(+), Lauren type(+), invasion(+), TNM(+), IPF | [97] |
TCGA/GEO (T vs. no-T) | ↑ | Lymph node metastasis(+), distant metastasis(+), TNM(+), 5-y OS(+), IPF | [99] | |
GEO (T vs. no-T) | ↑ | 3-y OS(+) | [100] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Meng, X.; Bai, X.; Ke, A.; Li, K.; Lei, Y.; Ding, S.; Dai, D. Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications. Biomolecules 2024, 14, 608. https://doi.org/10.3390/biom14060608
Meng X, Bai X, Ke A, Li K, Lei Y, Ding S, Dai D. Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications. Biomolecules. 2024; 14(6):608. https://doi.org/10.3390/biom14060608
Chicago/Turabian StyleMeng, Xiangyu, Xiao Bai, Angting Ke, Kaiqiang Li, Yun Lei, Siqi Ding, and Dongqiu Dai. 2024. "Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications" Biomolecules 14, no. 6: 608. https://doi.org/10.3390/biom14060608